Scarica l'app Stockscreener
8.9527
48.95%
2.7427
Precedente Chiudi:
$6.21
Aprire:
$14.745
Volume 24 ore:
21.44M
Relative Volume:
3.66
Capitalizzazione di mercato:
$4.50M
Reddito:
-
Utile/perdita netta:
$-8.74M
Rapporto P/E:
-4.3672
EPS:
-2.05
Flusso di cassa netto:
$-8.25M
1 W Prestazione:
+48.48%
1M Prestazione:
+6,839%
6M Prestazione:
+79.26%
1 anno Prestazione:
-77.87%
Intervallo 1D:
$8.54
$15.90
Intervallo di 1 settimana:
$5.94
$15.90
Portata 52W:
$0.0927
$62.60
Glucotrack Inc Stock (GCTK) Company Profile
Nome
Glucotrack Inc
Settore
Industria
Telefono
972 (8) 675-7878
Indirizzo
301 RT 17 NORTH, RUTHERFORD
Confronta GCTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
8.8171 | 4.50M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
521.90 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
170.41 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.42 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
257.50 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
221.17 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Glucotrack Inc Borsa (GCTK) Ultime notizie
Glucotrack announces 1:60 reverse stock split - Investing.com
GlucoTrack Implements Reverse Stock Split - TipRanks
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements - mx.advfn.com
Glucotrack announces 1-for-60 reverse stock split effective June 16 By Investing.com - Investing.com South Africa
Glucotrack announces 1-for-60 reverse stock split effective June 16 - Investing.com Nigeria
GlucoTrack Announces 1-for-60 Reverse Stock Split - TipRanks
Glucotrack Implements Major 1-for-60 Reverse Split: What This Means for Your Investment - Stock Titan
Glucotrack’s Innovative Approach to Diabetes Management Sets New Standards - citybuzz -
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management - Nasdaq
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions - mx.advfn.com
GlucoTrack to Present at ADA Scientific Sessions - TipRanks
Revolutionary Diabetes Tech: Glucotrack's 3-Year Implantable Monitor Eliminates Daily Finger Pricks - Stock Titan
GCTK stock plunges to 52-week low, hits $0.13 By Investing.com - Investing.com South Africa
GCTK stock plunges to 52-week low, hits $0.13 - Investing.com India
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives - The Globe and Mail
Glucotrack appoints new board member with diabetes tech expertise By Investing.com - Investing.com South Africa
Glucotrack appoints new board member with diabetes tech expertise - Investing.com
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - The Manila Times
GlucoTrack (NASDAQ:GCTK) Trading Down 0.2% – Time to Sell? - Defense World
GlucoTrack Approves Key Proposals at Annual Meeting - TipRanks
GCTK stock plunges to 52-week low, touches $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, touches $0.13 By Investing.com - Investing.com Nigeria
GlucoTrack Establishes Patient Advisory Board for CBGM - TipRanks
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development - The Manila Times
Glucotrack, Inc. Forms Patient Advisory Board to Enhance Development of Continuous Blood Glucose Monitor - Nasdaq
Groundbreaking 3-Year Implantable Glucose Monitor Gets Patient-Led Development at Glucotrack - Stock Titan
Glucotrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Innovative Continuous Blood Glucose Monitor Shows Promise in First Human Trial - citybuzz -
GlucoTrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack, Inc. SEC 10-Q Report - TradingView
Glucotrack, Inc. Advances Continuous Blood Glucose Monitoring Technology with Clinical Study Initiation in Australia by Q3 2025 - Nasdaq
Glucotrack Reports First Quarter 2025 Financial Results And Recent Corporate Highlights - marketscreener.com
Breakthrough: Glucotrack's Implantable Diabetes Monitor Hits Clinical Milestone, FDA Decision Expected Q4 - Stock Titan
Glucotrack gains HREC approval for clinical study of CBGM device - Yahoo Finance
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients - FinancialContent
Certain Options of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
GlucoTrack Gains Approval for Long-Term Clinical Study - TipRanks
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor - The Manila Times
Geode Capital Management LLC Increases Stock Holdings in GlucoTrack, Inc. (NASDAQ:GCTK) - Defense World
GlucoTrack Inc (GCTK) can make a big difference with a little luck - Sete News
Medtech CEO Shares Lessons From FIH Implantable Glucose Monitor Trial - Clinical Leader
GlucoTrack Releases Investor Presentation on April 29 - TipRanks
GlucoTrack Inc (NASDAQ:GCTK) stock crossing the finish line today - uspostnews.com
Can GlucoTrack Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Now Is The Time To Build A Position In GlucoTrack Inc (NASDAQ:GCTK) - Marketing Sentinel
Glucotrack Inc Azioni (GCTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):